MedTrace Logo

Effects of Diabetes Medications on Adrenal Function and Intestinal Microbiota

NCT04151849 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 23

Last updated 2023-02-21

No results posted yet for this study

Summary

The primary aim of this observational study is to describe the effects of glucagon-like peptide-1 (GLP-1) receptor agonists and Sodium-Glucose Co-transporter 2 inhibitors ( SGLT-2 inhibitors) on adrenal function. Secondary endpoint is change in intestinal microbiota.

Conditions

Interventions

DRUG

GLP-1 receptor agonist

Treatment with GLP-1 agonist for up to 1 year.

DRUG

SGLT2 inhibitor

Treatment with SGLT2 inhibitor for up to 1 year

Sponsors & Collaborators

  • University of Tartu

    lead OTHER

Principal Investigators

  • Vallo Volke, MD, PhD · University of Tartu, Institute of Biomedicine and Translational Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-07
Primary Completion
2023-01-23
Completion
2023-01-23

Countries

  • Estonia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04151849 on ClinicalTrials.gov